Company news
COSCIENS Biopharma Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming GRS and IGF Society Congress
October 10, 2012
Aeterna Zentaris Announces Share Consolidation to Regain NASDAQ Compliance
October 3, 2012
Aeterna Zentaris Presented Poster on Oral Prostate Cancer Vaccine, AEZS-120, at International Urology Conference in Japan
October 2, 2012
Aeterna Zentaris Provides Update on NDA Filing for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
September 26, 2012
Aeterna Zentaris Granted Patent by European Patent Office for AEZS-130 in Growth Hormone Deficiency Diagnosis
September 25, 2012
Aeterna Zentaris to Present Poster on Oral Prostate Cancer Vaccine Candidate, AEZS-120, at Upcoming International Urology Conference in Japan
September 20, 2012
Aeterna Zentaris to Present at Rodman & Renshaw 14th Annual Global Investment Conference in New York
September 5, 2012
Aeterna Zentaris to Present at Stifel Nicolaus Healthcare Conference in Boston
August 29, 2012
Aeterna Zentaris Announces First Patient Recruited for Phase 2A Trial in Cancer Cachexia with AEZS-130
August 28, 2012
Aeterna Zentaris Reports Second Quarter 2012 Financial and Operating Results
August 14, 2012
Aeterna Zentaris to Present Preclinical Data for PI3K/Erk 1/2 Inhibitor, AEZS-136, at ACS National Meeting
August 13, 2012
Aeterna Zentaris to Announce Second Quarter 2012 Financial and Operating Results on August 14, 2012
August 8, 2012
Aeterna Zentaris Granted Patent in the U.S. for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
August 7, 2012
Aeterna Zentaris: Preclinical Data for AEZS-108 in Bladder Cancer Published Online in Oncotarget
July 26, 2012
Aeterna Zentaris Requests Fast Track Designation from the FDA for AEZS-130 as Diagnostic Test for Adult Growth Hormone Deficiency
July 24, 2012
Aeterna Zentaris to Present at 7th Annual JMP Securities Healthcare Conference in New York
July 5, 2012
Aeterna Zentaris: Partner Yakult Initiates Phase 1 Trial in Multiple Myeloma with Perifosine in Japan
June 28, 2012
Aeterna Zentaris: Final Phase 3 Results for AEZS-130 in Adult Growth Hormone Deficiency Presented at ENDO Meeting
June 26, 2012
Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma
June 21, 2012
Aeterna Zentaris Learns of Class Action Lawsuits Filed and Denies Allegations
June 19, 2012
Aeterna Zentaris: Phase 2 Data for Perifosine as Monotherapy for Renal Cell Carcinoma Published in June Issue of Cancer
June 18, 2012
Aeterna Zentaris: Phase 3 Results for AEZS-130 in AGHD to be Presented at Upcoming ENDO Meeting
June 14, 2012
Aeterna Zentaris: Poster on Phase 1 Results for Perifosine in Neuroblastoma to be Presented at Upcoming Neuroblastoma Research Conference in Toronto
June 13, 2012
Aeterna Zentaris: Phase 1 Data for Perifosine in Multiple Myeloma Published in the British Journal of Haematology
June 5, 2012
Aeterna Zentaris: Phase 3 Data for Perifosine in Colorectal Cancer Presented at ASCO Meeting
June 4, 2012
Aeterna Zentaris: Article on Perifosine as Potential Novel Approach to the Treatment of Mesothelioma Published in Plos One
May 31, 2012
Aeterna Zentaris Reports First Quarter 2012 Financial and Operating Results
May 9, 2012
Aeterna Zentaris Regains North American Rights for Perifosine from Keryx
May 7, 2012
Aeterna Zentaris to Present at 11th Annual JMP Securities Research Conference in San Francisco
May 3, 2012
Aeterna Zentaris to Announce First Quarter 2012 Financial and Operating Results and Hold Annual Shareholders Meeting on May 9, 2012
May 1, 2012
Aeterna Zentaris Presents Preclinical Data for Its Anti-Cancer PI3K/ Erk 1/2 Inhibitor, AEZS-136, at AACR Meeting
April 3, 2012
Aeterna Zentaris Announces Top-Line Data from the Perifosine Phase 3 Trial in Refractory Advanced Colorectal Cancer
April 2, 2012
Aeterna Zentaris to Present at Needham Healthcare Conference in New York
March 29, 2012
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2011 Financial and Operating Results
March 27, 2012
Aeterna Zentaris to Present Preclinical Data for Anticancer Compounds Perifosine and AEZS-136 at Upcoming AACR Meeting
March 26, 2012
Aeterna Zentaris to Announce Fourth Quarter and Full Year 2011 Financial and Operating Results on March 27, 2012
March 20, 2012
Michael E. DeBakey VA Medical Center Initiates Phase 2A Trial in Cancer Cachexia with Aeterna Zentaris' Ghrelin Agonist, AEZS-130
March 8, 2012
Aeterna Zentaris to Present at Cowen and Company 32nd Annual Health Care Conference in Boston
February 29, 2012
Aeterna Zentaris to Present at BIO CEO Investor and RBC Capital Markets Global Healthcare Conferences in New York
February 7, 2012
Aeterna Zentaris Reports Updated Phase 1 Trial Results for AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer at ASCO GCS Meeting
February 3, 2012
Aeterna Zentaris: Updated Interim Phase 1 Trial Results for AEZS-108 in Prostate Cancer To Be Presented at Upcoming ASCO GCS Meeting in San Francisco
January 26, 2012
Aeterna Zentaris Announces Collaboration with Ventana Medical Systems, Inc. to Develop Companion Diagnostic in Cancer for AEZS-108
January 5, 2012
Aeterna Zentaris Partner, Yakult Honsha, Initiates Phase 1/2 Trial with Perifosine in Colorectal Cancer in Japan
January 3, 2012
Aeterna Zentaris: Encouraging Clinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
December 13, 2011
Aeterna Zentaris: Encouraging Preclinical Data for Perifosine in Hodgkin Lymphoma Presented at ASH Meeting
December 12, 2011
Aeterna Zentaris Presents Positive Preclinical Data in Breast Cancer on AEZS-131, a Highly Selective Erk 1/2 Inhibitor, at San Antonio Breast Cancer Symposium
December 9, 2011
Aeterna Zentaris: Presentations on Perifosine Scheduled at Upcoming ASH Meeting in San Diego, California
December 5, 2011
Aeterna Zentaris: FDA Grants IND to Investigator at Baylor College of Medicine for Phase 2A Trial with AEZS-130 in Cancer Cachexia
November 28, 2011
Aeterna Zentaris and Hikma Pharmaceuticals Sign a Commercialization and Licensing Agreement for Lead Oncology Compound, Perifosine, for Middle East and North Africa (MENA) Region
November 23, 2011
Aeterna Zentaris to Present at Upcoming Piper Jaffray and Oppenheimer Healthcare Conferences in New York
November 22, 2011
Decks
The 5 newest of 7 decks. Every deck is listed under its year.
- Investor Presentation (September 2026)
Investor deck · 14 slides · September 2026
- Aeterna Zentaris — Investor Presentation (January 2022)
Investor deck · 30 slides · Jan 26, 2022
- Aeterna Zentaris — Investor Presentation (October 2021)
Investor deck · 29 slides · Oct 7, 2021
- Aeterna Zentaris — H.C. Wainwright 23rd Annual Global Investment Conference 2021
Conference · 27 slides · Sep 13, 2021
- Aeterna Zentaris — Investor Presentation (March 2021)
Investor deck · 26 slides · Mar 19, 2021